Long-term follow up study after transplantation of human iPSC-derived dopaminergic progenitors in the treatment of Parkinson's Disease

Long-term follow up study after transplantation of human iPSC-derived dopaminergic progenitors in the treatment of Parkinson's Disease - Long-term follow up study after transplantation of human iPSC-derived dopaminergic progenitors in the treatment of Parkinson's Disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048476

Enrollment

Registered

2022-07-26

Start date

2022-07-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The study participants enrolled in the preceding clinical trial, transplanted human iPS cell-derived dopaminergic progenitors and completed the observation period of the clinical trial.

Exclusion criteria

Exclusion criteria: 1. Serious communication problems (to ensure safety during examinations). 2. Bad general condition (such as abnormal vital signs). 3. Serious infectious and other complications. 4. Women who are pregnant or may be pregnant. Women who are breastfeeding. 5. Participants who are judged to be inappropriate to be involved by the investigators.

Design outcomes

Primary

Measure	Time frame
Observation of transplanted iPSC-derived dopaminergic progenitors [18F]-FDOPA PET [With Carbidopa (Lodosyn)], [123I]-ioflupane SPECT and 7 tesla MRI	—

Secondary

Measure	Time frame
Evaluation of motor and non-motor symptoms Evaluation of clinical and laboratory examinations	—

Countries

Japan

Contacts

Public ContactNobukatsu Sawamoto

Kyoto University Hospital Department of Neurology

neuroofc@kuhp.kyoto-u.ac.jp075-751-3771

Outcome results